July 2 (Reuters) - Celea Therapeutics, linked to PureTech Health, on Thursday completed a $180 million financing round for a late-stage trial of its lung disease drug, deupirfenidone, in patients with ...
Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's ...
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to IPF ...
Boston biotech Celea Therapeutics raised $180 million from RA Capital, Leaps by Bayer and others to fund a Phase 3 trial of ...
PureTech Health(NASDAQ:PRTC) reported its second quarter 2025 earnings on Aug. 28, 2025, highlighting a cash balance of just under $320 million at the end of the first half of 2025, a reduction in ...
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Daphne Zohar, who founded Boston ...
Roche will work to enable oral administration of its antisense oligonucleotide platform using PureTech Health’s milk-derived exosome technology, through a collaboration that PureTech said today could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results